Kyjov 1

Researchers are evaluating tozorakimab as an additional treatment to standard care in adults hospitalized with viral lung infection who need supplemental oxygen. The study aims to determine if tozorakimab can help prevent death or the need for invasive mechanical ventilation or extracorporeal membrane oxygenation. This Phase III trial involves a large group of participants to assess the safety and effectiveness of this approach. Participants are randomly assigned to one of two groups one group receives a single intravenous dose of tozorakimab on the first day, while the other group receives a matching placebo. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. This helps ensure unbiased results. The treatments are given once, and participants continue to receive standard care during the trial. During the study, participants are closely monitored and evaluated up to 60 days after treatment. Researchers track important outcomes such as death rates, progression to invasive ventilation, days alive outside intensive care, and oxygen use. They also assess clinical progression using a World Health Organization scale and monitor for any anti-drug antibodies. The trial lasts until November 2027, with multiple assessments throughout to understand the treatments impact and safety.

Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to standard care in hospitalized adults with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, double-blind study aims to compare trimodulin plus standard care against placebo plus standard care. The study also investigates detailed pharmacokinetic and pharmacodynamic properties of trimodulin. Participants will be randomly assigned to receive either trimodulin a human immunoglobulin solution containing IgM, IgA, and IgG or a placebo human albumin 1% via intravenous infusion once daily for five consecutive days alongside standard care. After treatment, participants will enter a follow-up phase lasting up to 23 days, including an end-of-follow-up visit or phone call on day 29. If still hospitalized after day 29, extended follow-up continues until discharge or day 90, followed by a closing visit or call around day 91. During the study, participants undergo various assessments including monitoring of mortality rates up to 28 and 90 days, changes in organ failure scores, clinical cure of pneumonia, ventilator and oxygen use, ICU and hospital stay durations, readmission rates, adverse events, lab tests, electrocardiograms, and vital signs. Safety evaluations and outcome measurements occur throughout treatment and follow-up, with total participation lasting up to approximately 90 days.

Researchers are studying VE303, a live biotherapeutic product made of nonpathogenic bacteria strains, to evaluate its safety and effectiveness in preventing recurrent Clostridioides difficile infection CDI. This Phase 3 trial compares VE303 to a placebo in participants who recently completed standard antibiotic treatment for CDI. The study focuses on two groups those with recurrent CDI and individuals at high risk for primary CDI recurrence. Participants will receive either VE303 or a matching placebo capsule three times daily for 14 days, following 10 to 21 days of standard antibiotic therapy for CDI. VE303 capsules contain the study bacteria, while placebo capsules contain a non-active substance identical in appearance. Both groups complete this treatment regimen as part of the trial. During the study, participants are monitored for safety and CDI recurrence up to 8 weeks after treatment starts. Researchers collect stool samples and track symptoms to assess recurrence rates. The study uses a randomized, double-blind design to ensure unbiased results, and participants are followed closely through the treatment and observation periods, which last several weeks.